Publication details
Úprava guidelines ACC pro léčbu srdečního selhání v roce 2021
| Title in English | 2021 ACC update of the heart failure guidelines |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | COR ET VASA |
| MU Faculty or unit | |
| Citation | |
| web | https://actavia.e-coretvasa.cz/artkey/cor-202102-0005_2021-acc-update-of-the-heart-failure-guidelines.php |
| Doi | http://dx.doi.org/10.33678/cor.2021.033 |
| Keywords | ARNI; Guidelines; Heart failure; SGLT2 inhibitors |
| Description | The American College of Cardiology has published an update of the heart failure guidelines treatment in the beginning of the year 2021. We bring short information about this document. It is expected that the European Society of Cardiology will publish new European guidelines this year, which will probably confirm the increasing indication for sacubitril valsartan (ARNI) and for SGLT2 inhibitors, as a new drug class for heart failure treatment. The percutaneous access for the treatment of mitral regurgitation is also a new one. |